68 related articles for article (PubMed ID: 8305685)
1. [[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy].
Cordes M; Hosten N; Gräf KJ; Wenzel KW; Venz S; Keske U; Eichstädt H; Felix R
Rofo; 1994 Jan; 160(1):11-5. PubMed ID: 8305685
[TBL] [Abstract][Full Text] [Related]
2. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
3. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
4. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
8. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Kahaly G; Diaz M; Just M; Beyer J; Lieb W
Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
[TBL] [Abstract][Full Text] [Related]
9. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptors in the orbits.
Durak I; Durak H; Ergin M; Yürekli Y; Kaynak S
Clin Nucl Med; 1995 Mar; 20(3):237-42. PubMed ID: 7750218
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatin receptor scintigraphy in endocrine orbitopathy].
Diaz M; Kahaly G; Mühlbach A; Bockisch A; Beyer J; Hahn K
Rofo; 1994 Dec; 161(6):484-8. PubMed ID: 7803769
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
[TBL] [Abstract][Full Text] [Related]
17. The role of octreoscan in thyroid eye disease.
Krassas GE; Kahaly GJ
Eur J Endocrinol; 1999 May; 140(5):373-5. PubMed ID: 10229898
[TBL] [Abstract][Full Text] [Related]
18. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
19. Clinical diagnostic application of 111In-DTPA-octreotide scintigraphy in small cell lung cancer.
Vaccarili M; Lococo A; Fabiani F; Staffilano A
Tumori; 2000; 86(3):224-8. PubMed ID: 10939603
[TBL] [Abstract][Full Text] [Related]
20. 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas.
Luyken C; Hildebrandt G; Scheidhauer K; Krisch B; Schicha H; Klug N
Acta Neurochir (Wien); 1994; 127(1-2):60-4. PubMed ID: 7942184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
